Fig. 5.

Metabolic vascular and systemic effects of GLP1RAs potentially reduce the burden of cardiovascular risk and HFpEF deterioration. GLP1RAs act directly on pancreatic beta and alpha cells, the gastrointestinal tract, and the central nervous system to improve glucometabolic homeostasis and indirectly improve circulating lipid profiles by reducing hepatic steatosis. GLP1RAs, synthetic glucagon-like peptide receptor agonists; HFpEF, heart failure with preserved ejection fraction; eGFR, estimated glomerular filtration rate; GI, gastrointestinal.